Outcomes following pacemaker implantation after transcatheter aortic valve implantation with C ore V alve ® devices: Results from the FRANCE 2 R egistry

Aims Permanent pacemaker (PPM) implantation following high‐degree atrioventricular block is frequently required after transcatheter aortic valve implantation (TAVI) using CoreValve ® . Recent improvement of the delivery system (CoreValve Accutrak ® ) aimed to ease delivery and reduce the PPM rate. Our study evaluated the incidences of PPM implantation following use of CoreValve ® or CoreValve Accutrak ® and the clinical outcome of these patients. Methods and results A total of 883 patients (82 ± 7 years; 41.3% female) with severe symptomatic aortic stenosis and self‐expanding bioprosthesis implantation were included between January 2010 and October 2011 in 29 centers from the FRANCE 2 Registry. Follow‐up data were available in 833 patients. CoreValve ® and CoreValve Accutrak ® were used in 343 (41.2%) and 490 (58.8%) patients, respectively. During a mean follow‐up of 242 ± 179 days, all‐cause mortality was similar in patients with versus without PPM implantation (16.3 vs. 16.9%, P  = 0.832).There was no significant difference in the PPM incidence in CoreValve ® and CoreValve Accutrak ® patients (30.4% vs. 27.5%, P  = 0.846). Conclusion PPM implantation remained frequent after TAVI using CoreValve Accutrak ® . All‐cause mortality was similar in patients with or without PPM implantation. The new device failed to show a significant decrease in PPM implantation incidence after TAVI. © 2015 Wiley Periodicals, Inc.